>
MaxCyte Inc logo

MXCT - MaxCyte Inc Share Price

845p -3.0  -0.4%

Last Trade - 2:15pm

Sector
Healthcare
Size
Mid Cap
Market Cap ÂŁ718.1m
Enterprise Value ÂŁ693.9m
Revenue ÂŁ17.6m
Position in Universe 509th / 1820
Bullish
Bearish
Unlock MXCT Revenue
Momentum
Relative Strength (%)
1m -9.23%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -20.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
7.16 9.29 12.3 14.0 16.7 21.6 26.2 32.9 +24.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, MaxCyte Increvenues increased 30% to $10.9M. Net loss decreased 36% to$6.1M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Lower net loss reflects Research anddevelopment - Balancing val decrease of 15% to $8M(expense), Interest and other expense decrease of 54% to$282K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MXCT
Graphical History

Revenue

MXCT Revenue Unlock MXCT Revenue

Net Income

MXCT Net Income Unlock MXCT Revenue

Normalised EPS

MXCT Normalised EPS Unlock MXCT Revenue

PE Ratio Range

MXCT PE Ratio Range Unlock MXCT Revenue

Dividend Yield Range

MXCT Dividend Yield Range Unlock MXCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MXCT EPS Forecasts Unlock MXCT Revenue
Profile Summary

MaxCyte, Inc. focuses on cell-based medicines. The Company provide high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. The Company’s platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. The Company is developing CARMA, its platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face challenges. The Company's products include instruments, processing assemblies and insourcing services. The Company's instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 31, 1998
Public Since March 29, 2016
No. of Shareholders: n/a
No. of Employees: 65
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 84,684,623
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MXCT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MXCT
Upcoming Events for MXCT
Monday 19th April, 2021 Estimate
Full Year 2020 MaxCyte Inc Earnings Release
Frequently Asked Questions for MaxCyte Inc
What is the MaxCyte Inc share price?

As of 2:15pm, shares in MaxCyte Inc are trading at 845p, giving the company a market capitalisation of ÂŁ718.1m. This share price information is delayed by 15 minutes.

How has the MaxCyte Inc share price performed this year?

Shares in MaxCyte Inc are currently trading at 845p and the price has moved by 0.475k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MaxCyte Inc price has moved by 0.366k% over the past year.

What are the analyst and broker recommendations for MaxCyte Inc?

Of the analysts with advisory recommendations for MaxCyte Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MaxCyte Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will MaxCyte Inc next release its financial results?

MaxCyte Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the MaxCyte Inc dividend yield?

MaxCyte Inc does not currently pay a dividend.

Does MaxCyte Inc pay a dividend?

MaxCyte Inc does not currently pay a dividend.

When does MaxCyte Inc next pay dividends?

MaxCyte Inc does not currently pay a dividend.

How do I buy MaxCyte Inc shares?

To buy shares in MaxCyte Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MaxCyte Inc?

Shares in MaxCyte Inc are currently trading at 845p, giving the company a market capitalisation of ÂŁ718.1m.

Where are MaxCyte Inc shares listed? Where are MaxCyte Inc shares listed?

Here are the trading details for MaxCyte Inc:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: MXCT
What kind of share is MaxCyte Inc?

Based on an overall assessment of its quality, value and momentum, MaxCyte Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a MaxCyte Inc share price forecast 2021?

Shares in MaxCyte Inc are currently priced at 845p. At that level they are trading at 19.38% discount to the analyst consensus target price of 1,048.13.

Analysts covering MaxCyte Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.198 for the next financial year.

How can I tell whether the MaxCyte Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MaxCyte Inc. Over the past six months, the relative strength of its shares against the market has been 63.37%. At the current price of 845p, shares in MaxCyte Inc are trading at 62.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MaxCyte Inc PE Ratio?

We were not able to find PE ratio data for MaxCyte Inc.

Who are the key directors of MaxCyte Inc?

MaxCyte Inc's management team is headed by:

Ronald Holtz - SVP
Douglas Doerfler - PRE
J. Stark Thompson - NEC
William Brooke - NID
Stanley Erck - NID
John Johnston - NID
Thomas Ross - EVP
Shruti Abbato - OTH
James Brady - VPR
Maher Masoud - EVP
Kathryn Wekselman - VPR
Richard Douglas - NID
Amanda Murphy - CFO
Who are the major shareholders of MaxCyte Inc?

Here are the top five shareholders of MaxCyte Inc based on the size of their shareholding:

Casdin Capital, LLC Hedge Fund
Percentage owned: 13.32% (11.3m shares)
Bost-Jackson, L.L.C. Corporation
Percentage owned: 4.48% (3.79m shares)
Harbert Management Corporation Corporation
Percentage owned: 4.12% (3.49m shares)
Canaccord Genuity Wealth Management Investment Advisor/Hedge Fund
Percentage owned: 3.87% (3.28m shares)
Marlborough UK Micro Cap Growth Retail Mutual Fund
Percentage owned: 3.87% (3.28m shares)
Similar to MXCT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.